Neuren Pharmaceuticals: Strong Growth Driven by Royalties and Pipeline Progress

Neuren Pharmaceuticals Limited (ASX: NEU) develops innovative treatments targeting rare and serious neurodevelopmental conditions. For the half-year ended June 30, 2025, the company reported revenue of AU$39.7 million, up 24% year-on-year, with net profit after tax rising 88% to AU$15.0 million. Growth was underpinned by AU$28.3 million in royalties from Acadia Pharmaceuticals, which markets DAYBUE™, the first approved treatment for Rett syndrome. Patient uptake in the US continues to expand, with European and Japanese market entry progressing through regulatory pathways.

Neuren is also advancing NNZ-2591, its second candidate, with a Phase 3 trial underway for Phelan-McDermid syndrome and additional indications under development. The company ended the period with AU$299.5 million in cash and investments, providing strong funding capacity. Strategic share buy-backs were completed, reflecting management’s confidence in long-term value creation.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com